Improving Chuanxiong Rhizoma quality standards using an effect-constituent index based bioassay

Area of Science:

• Pharmacology
• Phytochemistry
• Traditional Chinese Medicine (TCM)

Background:

• Chuanxiong Rhizoma is a vital TCM for blood circulation.
• Current quality control methods for TCMs often lack bioactivity correlation.
• Improving TCM quality standards is crucial for clinical efficacy.

Purpose of the Study:

• To develop a bioassay-based Effect-constituent Index (ECI) for Chuanxiong Rhizoma quality assessment.
• To identify active constituents responsible for the antiplatelet aggregation effects of Chuanxiong Rhizoma.
• To compare the efficacy of ECI with traditional chemical indicator methods.

Main Methods:

• High-performance liquid chromatography (HPLC) to analyze chemical constituents.
• Direct bioassay to measure antiplatelet aggregation effects.
• Pearson correlation analysis to link biopotency with compounds.
• Development of a multi-indicator synthetic evaluation method for ECI.

Main Results:

• All 10 Chuanxiong Rhizoma samples inhibited platelet aggregation with varying potencies.
• Ligustilide was identified as the primary active constituent for antiplatelet activity.
• The developed ECI correlated well with the biological potency of Chuanxiong Rhizoma extracts.
• ECI demonstrated superior accuracy in quality grading compared to chemical indicators.

Conclusions:

• The Effect-constituent Index (ECI) is a reliable tool for assessing Chuanxiong Rhizoma quality by integrating biopotency and chemical constituents.
• ECI effectively links TCM quality to chemical markers related to clinical effects.
• This approach offers a new paradigm for quality control of other blood-invigorating TCMs.